ArticlePoultry science2026
Dietary allicin supplementation inhibits hepatic CYP3A37 in chickens: Evidence from in vitro and in vivo models.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allicin, a natural compound with antibacterial and antioxidant properties, is a promising antibiotic-alternative feed additive. This study investigated its impact on cytochrome P450 3A37 (CYP3A37) in broilers. Broilers were fed a basal diet supplemented with 0, 40, or 80 mg/kg allicin for 42 days. In vivo results revealed a biphasic effect: CYP3A37 activity was induced on day 14 but significantly inhibited on days 28 and 42. This inhibition was accompanied by downregulation of CYP3A37 mRNA and protein expression. Consequently, allicin (80 mg/kg) altered the pharmacokinetics of the CYP3A37 substrate dapsone, increasing its AUC and decreasing its clearance. In vitro assays demonstrated that allicin acts as a non-competitive inhibitor of CYP3A37 with an IC50 of 57.31 μM and a Kᵢ of 85.53 μM, in a time- and concentration-dependent manner. In conclusion, long-term allicin supplementation inhibits CYP3A37, posing a potential risk for drug-drug interactions in veterinary practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.